The FDA approved a new blood test for colorectal cancer, simpler than other screening methods. Unlike colonoscopies, it may not detect precancerous growths but can identify early-stage cancers, potentially lowering deaths.
The test, named Shield, is designed by Guardant Health for individuals aged 45 and over at average risk. Despite limitations, it aims to encourage more screenings for colorectal cancer, the second-most common cause of cancer deaths in the U.S.
Collection
[
|
...
]